Nucelion, Pandorum Enter Ophthalmology Manufacturing Pact

Nucelion, a Bharat Biotech arm, has entered a manufacturing pact with Pandorum to develop ophthalmology therapies, according to Fortune India.

The arrangement covers two projects. Fortune India reported that the projects have a combined planned outlay of ₹16.97 crore, including up to ₹8 crore in funding under the central government’s Promotion of Research and Innovation in Pharma-MedTech Sector scheme.

Partnership centers on ophthalmology therapies

Fortune India described the agreement as a manufacturing pact between Nucelion and Pandorum focused on developing ophthalmology therapies. The report identifies Nucelion as an arm of Bharat Biotech.

For medical-device and life-sciences sales professionals following ophthalmology, the reported collaboration places manufacturing activity alongside therapy development. The supplied report summary does not provide further detail on the individual projects, the therapies involved, or the parties’ respective responsibilities.

Two projects carry planned outlay

The two projects have a combined planned outlay of ₹16.97 crore, Fortune India reported. That total includes up to ₹8 crore in funding through the central government’s Promotion of Research and Innovation in Pharma-MedTech Sector scheme.

The report links the funding to the scheme by name and places the projects within a pharma-medtech research and innovation context. It does not specify how the planned outlay is allocated between the two projects.

Reported points for commercial teams

• Nucelion and Pandorum are named as parties to a manufacturing pact.
• The stated development focus is ophthalmology therapies.
• Fortune India reported two projects with a combined planned outlay of ₹16.97 crore.
• The report cites up to ₹8 crore in funding under the Promotion of Research and Innovation in Pharma-MedTech Sector scheme.

Fortune India’s report establishes the partnership, therapy area, project count, planned outlay, and cited scheme funding. Additional operational and product-specific details were not included in the supplied evidence.